The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

H Miles Prince; Mark Bishton; Simon Harrison

doi:10.1080/10428190801950058

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

Leuk Lymphoma. 2008 Mar;49(3):385-7. doi: 10.1080/10428190801950058.

Authors

H Miles Prince¹, Mark Bishton, Simon Harrison

Affiliation

¹ Haematology Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

PMID: 18297514
DOI: 10.1080/10428190801950058

Abstract

Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.

Publication types

Comment

MeSH terms

Antineoplastic Agents
Enzyme Inhibitors / therapeutic use*
Histone Deacetylase Inhibitors*
Humans
Hydroxamic Acids / therapeutic use
Indoles
Multiple Myeloma / drug therapy*
Panobinostat
Treatment Outcome

Substances

Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Hydroxamic Acids
Indoles
Panobinostat
givinostat hydrochloride